IQVIA VP named new BerGenBio CMO

11 April 2022

Norwegian biopharma BerGenBio (OSE: BGBIO) has appointed experienced oncologist Cristina Oliva as chief medical officer.

Dr Oliva joins the Bergen-based company’s senior leadership team, heading up clinical development of BerGenBio’s selective AXL inhibitor programs.

"BerGenBio is on the frontier of developing novel, highly selective AXL inhibitors"She brings to the role more than 20 years of senior clinical development experience across big pharma, biotech and clinical research organizations (CROs). Her most recent post was vice president, oncology and head of the Oncology Center of Excellence at IQVIA (NYSE: IQV), where she led the development of decentralized trials and established and led the IQVIA oncology global scientific advisory board.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK